Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 ...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...
Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...
Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...
NeuroSense (NRSN) reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled ...
Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and ...
Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a ...
Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...
Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial missed the primary ...
DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...
Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, ...
Hope is preparing for close-out meetings with the FDA. Chang said the team is “hopeful to advance to a phase 3 confirmatory trial” of the stem cell therapy candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback